Human prothrombin complex

This product contains four coagulation factors II, VII, IX, and X that are synthesized in the liver and depend on vitamin K. Vitamin K deficiency and severe liver disease can cause the deficiency of these four factors. And the deficiency of any of the above factors can lead to coagulation disorders. Infusion of this product can increase the concentration of coagulation factors II, VII, IX, and X in the blood.

Main components: coagulation factors II, VII, IX, and X.

This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.

Usage: 1. This product is for intravenous infusion only and should be used under the strict supervision of a clinical physician; 2. Before use, preheat this product and sterile water for injection or 5% glucose injection to 20-25°C, inject the preheated sterile water for injection or 5% glucose injection according to the amount indicated on the bottle label, and gently rotate until the product is completely dissolved (be careful not to produce a lot of foam); 3. It can be diluted with sodium chloride injection or 5% glucose injection to 50-100 ml, and then intravenously dripped with a blood transfusion device with a filter device. The drip speed should be slow at the beginning, and the drip speed should be slightly increased after 15 minutes. Generally, each bottle of 200 plasma equivalent units (PE) will drip in about 30-60 minutes; 4. During the drip, the physician should pay attention to the use at any time. If clinical symptoms and signs of disseminated intravascular coagulation or thrombosis are found, the use should be stopped immediately. And heparin antagonism. Dosage: (1) The dosage varies with the degree of factor deficiency. Generally, 10 to 20 plasma equivalent units are transfused per kg of body weight. Thereafter, for patients with factor VII deficiency, the dosage can be reduced every 6 to 8 hours; for patients with factor IX deficiency, the dosage can be reduced every 24 hours; for patients with factor II and factor X deficiency, the dosage can be reduced every 24 to 48 hours. The dosage can be reduced as appropriate and usually lasts for 2 to 3 days. (2) When the amount of bleeding is large or major surgery is required, the dosage can be appropriately increased according to the patient's condition. (3) For patients with prolonged prothrombin time who are scheduled to undergo splenectomy, the medication should be used before surgery. The medication should be used during and after surgery based on the patient's condition.

Generally there are no adverse reactions. Rapid infusion may cause fever, flushing, headache and other side effects. The above symptoms will disappear if the infusion is slowed down or stopped.

There are no known contraindications when the indications are strictly controlled.

Do not use with other medicines.

Store below 8°C away from light.

200 IU/bottle (each bottle contains 200 IU of factors II, IX, and X, and 80 IU of factor VII).

Nuoyi Biopharmaceutical Co., Ltd.

• Founded in:

  1989-04-22

• Address:

  Room 1108, 11th Floor, Building 2, No. 1508, Kunyang Road, Minhang District, Shanghai

• Tax NO.:

  91310000132217471A

• Registered Funds:

  874.858359 yuan

• Email:

  Log in to view